Multiple clinical vertebral fractures following denosumab discontinuation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis: A GRADE-assessed systematic review and meta-analysis.Medicine · 2026
   Pooled it
2. Conservative Treatments in the Management of Acute Painful Vertebral Compression Fractures: A Systematic Review and Network Meta-Analysis.JAMA network open · 2024
   Pooled it
3. No Increase in Fractures After Stopping Hormone Therapy: Results From the Women's Health Initiative.The Journal of clinical endocrinology and metabolism · 2017
   Trial
4. Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
   Trial
5. Discontinuing Long-Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?Clinical pharmacology and therapeutics · 2026
   Review
6. Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment-Naive Patients Compared With Zoledronate.Clinical pharmacology and therapeutics · 2026
   Article
7. Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
   Article
8. Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
   Article
9. The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
   Observational
10. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
11. Trabecular bone deterioration in a postmenopausal female suffering multiple spontaneous vertebral fractures due to a delayed denosumab injection - A post-treatment re-initiation bone biopsy-based case study.Bone reports · 2023
    Article
12. Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.Journal of clinical medicine · 2023
    Review
13. The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review.Journal of bone metabolism · 2022
    Article
14. Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.Acta bio-medica : Atenei Parmensis · 2022
    Review
15. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Observational
16. Single pharmacy governed denosumab home administration: optimal adherence by means of a fracture liaison service (FLS) and home care collaboration.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
17. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature.Endocrinology and metabolism (Seoul, Korea) · 2022
    Review
18. Stop the denosumab delay! The effect of implementing an automatic reminder in the electronic medical record.Archives of osteoporosis · 2022
    Article
19. Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China.Frontiers in pharmacology · 2022
    Article
20. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Article

Corrections and comments

• Comment on
  Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as